Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cyclo Therapeutics, Inc. (CYTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.0200+0.0200 (+1.00%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close2.0000
Open1.9900
Bid2.0000 x 900
Ask2.2400 x 3000
Day's Range1.9300 - 2.0900
52 Week Range1.8800 - 10.0800
Volume8,108
Avg. Volume23,600
Market Cap17.001M
Beta (5Y Monthly)-0.75
PE Ratio (TTM)N/A
EPS (TTM)-1.8240
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CYTH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cyclo Therapeutics, Inc.
    Daily – Vickers Top Insider Picks for 03/10/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • Business Wire

    Cyclo Therapeutics to Present at the 2022 NPC Patient and Family Conference Hosted by the Australian NPC Disease Foundation

    GAINESVILLE, Fla., June 21, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that Professor Caroline Hastings, MD will present at the 2022 NPC Conference hosted by the Australian NPC Disease Foundation being held virtually June 23-24, 2022.

  • Business Wire

    Cyclo Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

    GAINESVILLE, Fla., May 18, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a late clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics, will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, FL and virtually.

  • Business Wire

    Cyclo Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

    GAINESVILLE, Fla., May 12, 2022--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) ("Cyclo Therapeutics" or the "Company"), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2022 and provided a business update.

Advertisement
Advertisement